During the past decade, Central Plains Eye MDs conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Central Plains Eye MDs" are "Exudative Age-related Macular Degeneration" (1 trials), "Macular Edema" (1 trials), "Nonproliferative Diabetic Retinopathy" (1 trials) and "Retinal Vein Occlusion" (1 trials). Many other conditions were trialed in "Central Plains Eye MDs" in a lesser frequency.

Most popular intervention types in "Central Plains Eye MDs" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea" (1 trials), "0.5 mg iSONEP" (1 trials), "4.0 mg iSONEP" (1 trials), "AKB-9778" (1 trials) and "Lucentis or Avastin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Central Plains Eye MDs" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Central Plains Eye MDs". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Central Plains Eye MDs, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Central Plains Eye MDs, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".